Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
569.00    3.00 (0.53%)
Bid:
569.00
Ask:
570.00
Spread: 1.00 (0.176%)
Market Cap: £2.52b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Directorate Change

3 Jul 2023 07:02

RNS Number : 6479E
Tate & Lyle PLC
03 July 2023
 

Directorate Change

 

Tate & Lyle PLC (Tate & Lyle) announces that Dr Gerry Murphy has decided to step down as Chair of the Board of Tate & Lyle, a position he has held for more than six years to take up the position of Chair of the Board of Tesco plc. Dr Murphy will remain Chair of Tate & Lyle until 1 September 2023.

 

The Board has begun a process to appoint a successor to Dr Murphy. Mr Paul Forman, Senior Independent Director, is leading this process and a further announcement will be made in due course.

 

As previously announced, Mr Forman was due to retire from the Tate & Lyle Board at the AGM on 27 July 2023. In light of Dr Murphy's decision, Mr Forman will continue as a non-executive director and as Senior Independent Director to allow time to complete the search process. The Board will therefore propose an additional resolution at the AGM in respect of Mr Forman's annual re-election as a non-executive director, in accordance with applicable corporate governance guidance. When the search for a new Chair has been concluded, Mr Forman will retire from the Board and Kim Nelson will take up the position of Senior Independent Director, as previously announced.

 

Pending the appointment of a new Chair, the Board has appointed Warren Tucker as Interim Chair of Tate & Lyle from 1 September 2023. Warren is currently Chair of the Audit Committee and will continue in this role during this interim period.

 

Nick Hampton, Chief Executive said: "Gerry has made a significant contribution to Tate & Lyle over the last six years. He has led the Board expertly through a major strategic transformation to reposition Tate & Lyle as a growth focussed global speciality food and beverage solutions business meeting growing consumer demand for healthier and tastier food and drink. It has been a pleasure to work alongside him. On behalf of the Board, we thank him for his leadership and wish him well in his new role."

 

Gerry Murphy, said: "It has been a privilege to serve as Chair of Tate & Lyle for the last six years, a company which I have known since my early years as a food scientist. Tate & Lyle, with its clear focus and ambitious purpose, its outstanding leadership team led by Nick Hampton and a very committed Board of Directors, is well-positioned to capture the growth opportunities that lie ahead. I would like to thank my fellow directors, and all my friends and colleagues in the Tate & Lyle family around the world for their support and stimulation since the day I joined the company in January 2017."

 

This announcement is made pursuant to LR 9.6.11R.

 

For more information contact Tate & Lyle PLC:

Christopher Marsh, VP Investor Relations

Tel: Mobile: +44 (0) 7796 192 688

 

Nick Hasell, FTI Consulting (Media)

Tel: Mobile: +44 (0) 7825 523 383

 

 

About Tate & Lyle: Supported by our 160-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients every day.

Through our expertise in sweetening, fortification, and mouthfeel, we develop ingredient solutions which reduce sugar, calories, and fat, add fibre and protein, and provide texture and stability in categories including beverage, dairy, bakery and snacks, and soups, sauces, and dressings.

We have more than 3,600 employees working in 58 locations across the world. Science, Solutions, Society is our brand promise and how we will achieve our purpose of Transforming Lives Through the Science of Food. By living our purpose we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2023, Tate & Lyle revenue totalled £1.75 billion. For more information, please visit https://www.tateandlyle.com or follow Tate & Lyle on Twitter, Linkedin, Facebook or YouTube.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOASSUSUEEDSELW
Date   Source Headline
21st Jan 20217:00 amRNSVivid Sehgal Appointed Chief Financial Officer
12th Jan 20213:30 pmRNSDirector/PDMR Shareholding
4th Jan 20213:05 pmRNSBlock listing Interim Review
4th Jan 20213:04 pmRNSTotal Voting Rights
30th Dec 20201:00 pmRNSBoard Changes
7th Dec 202011:06 amRNSDirector/PDMR Shareholding
1st Dec 20207:00 amRNSTATE & LYLE ACQUIRES SWEET GREEN FIELDS
5th Nov 20207:00 amRNSHalf-year Report
28th Oct 20207:00 amRNSTate & Lyle to acquire tapioca business
14th Oct 202011:00 amRNSDirector Declaration
7th Oct 20207:00 amRNSDirectorate Change
2nd Oct 202011:55 amRNSDirector/PDMR Shareholding
1st Oct 20202:30 pmRNSTotal Voting Rights
17th Sep 20207:30 amRNSBlock Listing
8th Sep 202010:00 amRNSDirector/PDMR Shareholding
1st Sep 202012:00 pmRNSTotal Voting Rights
5th Aug 20204:30 pmRNSDirector/PDMR Shareholding
3rd Aug 20202:00 pmRNSTotal Voting Rights
23rd Jul 20201:00 pmRNSResult of AGM
23rd Jul 20207:00 amRNSTrading Statement
2nd Jul 20205:45 pmRNSBlock listing Interim Review
1st Jul 20203:06 pmRNSRights attaching to the listed share capital
1st Jul 20203:05 pmRNSTotal Voting Rights
9th Jun 20203:00 pmRNSAnnual Financial Report
2nd Jun 20203:56 pmRNSDirector/PDMR Shareholding
21st May 20207:00 amRNSFinal Results
4th May 20207:00 amRNSTrading Update
1st May 20203:27 pmRNSTotal Voting Rights
3rd Apr 202011:00 amRNSDirector Declaration
1st Apr 202012:26 pmRNSTotal Voting Rights
6th Feb 20207:00 amRNSTrading Statement
30th Jan 202011:45 amRNSDirector/PDMR Shareholding
7th Jan 20202:00 pmRNSDirector/PDMR Shareholding
2nd Jan 202012:41 pmRNSBlock listing Interim Review
19th Dec 20192:00 pmRNSDirector/PDMR Shareholding
7th Nov 20197:00 amRNSHalf-year Report
3rd Oct 20193:06 pmRNSHolding(s) in Company
1st Oct 201910:14 amRNSTotal Voting Rights
19th Sep 20197:00 amRNSFULL PENSION SCHEME BUY-IN WITH LEGAL & GENERAL
6th Sep 201910:15 amRNSDirector/PDMR Shareholding
30th Aug 201912:00 pmRNSDirector Declaration
21st Aug 201910:00 amRNSDirector/PDMR Shareholding
5th Aug 20193:00 pmRNSIssue of Debt
1st Aug 20192:00 pmRNSTotal Voting Rights
25th Jul 201912:58 pmRNSResult of AGM
18th Jul 20193:00 pmRNSDirector/PDMR Shareholding
17th Jul 20197:02 amRNSChange to Executive Committee
1st Jul 201912:40 pmRNSBlock listing Interim Review
1st Jul 201912:38 pmRNSTotal Voting Rights
1st Jul 201912:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.